TickerKhojComparison · NSE · data 2026-11-02
Bafna Pharmaceuticals Limited vs Kopran Limited
In plain words
Size: Kopran Limited is about 1.1 times the market value of Bafna Pharmaceuticals Limited.
Valuation (P/E): Bafna Pharmaceuticals Limited 136.1 vs Kopran Limited 47.2.
Return on equity: Bafna Pharmaceuticals Limited 12.3% vs Kopran Limited 4.9%.
Profit growth over 3 years: Bafna Pharmaceuticals Limited -0.7% a year vs Kopran Limited -1.9% a year.
Debt to equity: Bafna Pharmaceuticals Limited 0.39 vs Kopran Limited 0.29.
Differences in the numbers, not a recommendation of either stock.
Side by side
| BAFNAPH | KOPRAN | |
|---|---|---|
| Price | ₹447.9 | ₹244.01 |
| Market cap | ₹1,060 cr | ₹1,156 cr |
| P/E | 136.1 | 47.2 |
| P/B | — | — |
| ROE | 12.3% | 4.9% |
| ROCE | 9.2% | 10.1% |
| Debt / equity | 0.39 | 0.29 |
| Operating margin | 3.7% | 8.7% |
| Dividend yield | 0.00% | 1.25% |
| Sales growth, 3 years (yearly) | 9.3% | 7.2% |
| Profit growth, 3 years (yearly) | -0.7% | -1.9% |
| 1-year return | 218.1% | 47.4% |
| Revenue, last 12 months | ₹143 cr | ₹700 cr |
| Net profit, last 12 months | ₹8 cr | ₹25 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹0 cr | ₹7 cr |
| Quarter profit vs a year earlier | -97.6% | -10.1% |
| Promoter holding | 75.00% | 41.82% |
| Health check | Average (4.5/10) | Average (5.4/10) |
Common questions
Which has a higher P/E, Bafna Pharmaceuticals Limited or Kopran Limited?
Bafna Pharmaceuticals Limited trades at the higher P/E (136.1 against 47.2). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Bafna Pharmaceuticals Limited (12.3% against 4.9%).
Which carries more debt?
Bafna Pharmaceuticals Limited has the higher debt-to-equity ratio (0.39 against 0.29).